Literature DB >> 23922447

Hepatocyte nuclear factor 1 regulates the expression of the organic cation transporter 1 via binding to an evolutionary conserved region in intron 1 of the OCT1 gene.

Valerie P O'Brien1, Kristin Bokelmann, Jacqueline Ramírez, Karoline Jobst, Mark J Ratain, Jürgen Brockmöller, Mladen V Tzvetkov.   

Abstract

The organic cation transporter 1 (OCT1), also known as solute carrier family 22 member 1, is strongly and specifically expressed in the human liver. Here we show that the hepatocyte nuclear factor 1 (HNF1) regulates OCT1 transcription and contributes to the strong, liver-specific expression of OCT1. Bioinformatic analyses revealed strong conservation of HNF1 binding motifs in an evolutionary conserved region (ECR) in intron 1 of the OCT1 gene. Electrophoretic mobility shift and chromatin immunoprecipitation assays confirmed the specific binding of HNF1 to the intron 1 ECR. In reporter gene assays performed in HepG2 cells, the intron 1 ECR increased SV40 promoter activity by 22-fold and OCT1 promoter activity by 13-fold. The increase was reversed when the HNF1 binding sites in the intron 1 ECR were mutated or the endogenous HNF1α expression was downregulated with small interfering RNA. Following HNF1α overexpression in Huh7 cells, the intron 1 ECR increased SV40 promoter activity by 11-fold and OCT1 promoter activity by 6-fold. Without HNF1α overexpression, the increases were only 3- and 2-fold, respectively. Finally, in human liver samples, high HNF1 expression was significantly correlated with high OCT1 expression (r = 0.48, P = 0.002, n = 40). In conclusion, HNF1 is a strong regulator of OCT1 expression. It remains to be determined whether genetic variants, disease conditions, or drugs that affect HNF1 activity may affect the pharmacokinetics and efficacy of OCT1-transported drugs such as morphine, tropisetron, ondansetron, tramadol, and metformin. Beyond OCT1, this study demonstrates the validity and usefulness of interspecies comparisons in the discovery of functionally relevant genomic sequences.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23922447      PMCID: PMC3781413          DOI: 10.1124/jpet.113.206359

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  52 in total

1.  ECR Browser: a tool for visualizing and accessing data from comparisons of multiple vertebrate genomes.

Authors:  Ivan Ovcharenko; Marcelo A Nobrega; Gabriela G Loots; Lisa Stubbs
Journal:  Nucleic Acids Res       Date:  2004-07-01       Impact factor: 16.971

2.  hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia.

Authors:  A Bazeos; D Marin; A G Reid; G Gerrard; D Milojkovic; P C May; H de Lavallade; P Garland; K Rezvani; J F Apperley; J M Goldman; L Foroni; J S Khorashad
Journal:  Leukemia       Date:  2010-05-06       Impact factor: 11.528

3.  The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin.

Authors:  M V Tzvetkov; S V Vormfelde; D Balen; I Meineke; T Schmidt; D Sehrt; I Sabolić; H Koepsell; J Brockmöller
Journal:  Clin Pharmacol Ther       Date:  2009-06-17       Impact factor: 6.875

Review 4.  Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy.

Authors:  Anne T Nies; Hermann Koepsell; Katja Damme; Matthias Schwab
Journal:  Handb Exp Pharmacol       Date:  2011

5.  Molecular cloning, functional characterization and genomic organization of four alternatively spliced isoforms of the human organic cation transporter 1 (hOCT1/SLC22A1).

Authors:  M Hayer; H Bönisch; M Brüss
Journal:  Ann Hum Genet       Date:  1999-11       Impact factor: 1.670

6.  Activation of the mouse TATA-less and human TATA-containing UDP-glucuronosyltransferase 1A1 promoters by hepatocyte nuclear factor 1.

Authors:  P Bernard; H Goudonnet; Y Artur; B Desvergne; W Wahli
Journal:  Mol Pharmacol       Date:  1999-09       Impact factor: 4.436

7.  Hepatocyte nuclear factor 1 alpha: a key mediator of the effect of bile acids on gene expression.

Authors:  Diana Jung; Gerd A Kullak-Ublick
Journal:  Hepatology       Date:  2003-03       Impact factor: 17.425

8.  Regulation of basal core promoter activity of human organic cation transporter 1 (OCT1/SLC22A1).

Authors:  Moto Kajiwara; Tomohiro Terada; Jun-ichi Asaka; Masayo Aoki; Toshiya Katsura; Iwao Ikai; Ken-ichi Inui
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-10-09       Impact factor: 4.052

9.  Hepatocyte nuclear factor 1 inactivation results in hepatic dysfunction, phenylketonuria, and renal Fanconi syndrome.

Authors:  M Pontoglio; J Barra; M Hadchouel; A Doyen; C Kress; J P Bach; C Babinet; M Yaniv
Journal:  Cell       Date:  1996-02-23       Impact factor: 41.582

10.  Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma.

Authors:  John C Chambers; Weihua Zhang; Joban Sehmi; Xinzhong Li; Mark N Wass; Pim Van der Harst; Hilma Holm; Serena Sanna; Maryam Kavousi; Sebastian E Baumeister; Lachlan J Coin; Guohong Deng; Christian Gieger; Nancy L Heard-Costa; Jouke-Jan Hottenga; Brigitte Kühnel; Vinod Kumar; Vasiliki Lagou; Liming Liang; Jian'an Luan; Pedro Marques Vidal; Irene Mateo Leach; Paul F O'Reilly; John F Peden; Nilufer Rahmioglu; Pasi Soininen; Elizabeth K Speliotes; Xin Yuan; Gudmar Thorleifsson; Behrooz Z Alizadeh; Larry D Atwood; Ingrid B Borecki; Morris J Brown; Pimphen Charoen; Francesco Cucca; Debashish Das; Eco J C de Geus; Anna L Dixon; Angela Döring; Georg Ehret; Gudmundur I Eyjolfsson; Martin Farrall; Nita G Forouhi; Nele Friedrich; Wolfram Goessling; Daniel F Gudbjartsson; Tamara B Harris; Anna-Liisa Hartikainen; Simon Heath; Gideon M Hirschfield; Albert Hofman; Georg Homuth; Elina Hyppönen; Harry L A Janssen; Toby Johnson; Antti J Kangas; Ido P Kema; Jens P Kühn; Sandra Lai; Mark Lathrop; Markus M Lerch; Yun Li; T Jake Liang; Jing-Ping Lin; Ruth J F Loos; Nicholas G Martin; Miriam F Moffatt; Grant W Montgomery; Patricia B Munroe; Kiran Musunuru; Yusuke Nakamura; Christopher J O'Donnell; Isleifur Olafsson; Brenda W Penninx; Anneli Pouta; Bram P Prins; Inga Prokopenko; Ralf Puls; Aimo Ruokonen; Markku J Savolainen; David Schlessinger; Jeoffrey N L Schouten; Udo Seedorf; Srijita Sen-Chowdhry; Katherine A Siminovitch; Johannes H Smit; Timothy D Spector; Wenting Tan; Tanya M Teslovich; Taru Tukiainen; Andre G Uitterlinden; Melanie M Van der Klauw; Ramachandran S Vasan; Chris Wallace; Henri Wallaschofski; H-Erich Wichmann; Gonneke Willemsen; Peter Würtz; Chun Xu; Laura M Yerges-Armstrong; Goncalo R Abecasis; Kourosh R Ahmadi; Dorret I Boomsma; Mark Caulfield; William O Cookson; Cornelia M van Duijn; Philippe Froguel; Koichi Matsuda; Mark I McCarthy; Christa Meisinger; Vincent Mooser; Kirsi H Pietiläinen; Gunter Schumann; Harold Snieder; Michael J E Sternberg; Ronald P Stolk; Howard C Thomas; Unnur Thorsteinsdottir; Manuela Uda; Gérard Waeber; Nicholas J Wareham; Dawn M Waterworth; Hugh Watkins; John B Whitfield; Jacqueline C M Witteman; Bruce H R Wolffenbuttel; Caroline S Fox; Mika Ala-Korpela; Kari Stefansson; Peter Vollenweider; Henry Völzke; Eric E Schadt; James Scott; Marjo-Riitta Järvelin; Paul Elliott; Jaspal S Kooner
Journal:  Nat Genet       Date:  2011-10-16       Impact factor: 38.330

View more
  14 in total

1.  PharmGKB summary: very important pharmacogene information for SLC22A1.

Authors:  Srijib Goswami; Li Gong; Kathleen Giacomini; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2014-06       Impact factor: 2.089

2.  OCT1 genetic variants are associated with postoperative morphine-related adverse effects in children.

Authors:  Rajiv Balyan; Xue Zhang; Vidya Chidambaran; Lisa J Martin; Tomoyuki Mizuno; Tsuyoshi Fukuda; Alexander A Vinks; Senthilkumar Sadhasivam
Journal:  Pharmacogenomics       Date:  2017-05-04       Impact factor: 2.533

3.  Carriers of genetic variants in the HNF1A gene are more common among dead opioid addicts than among living addicts.

Authors:  Anh Nguyen; Tore B Stage; Søren Feddersen; Dorte J Christoffersen; Mette Marie H Christensen; Per Damkier; Jørgen L Thomsen; Kim Brøsen
Journal:  Eur J Clin Pharmacol       Date:  2016-05-30       Impact factor: 2.953

4.  ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia.

Authors:  M Li; E L Seiser; R M Baldwin; J Ramirez; M J Ratain; F Innocenti; D L Kroetz
Journal:  Pharmacogenomics J       Date:  2016-11-15       Impact factor: 3.550

Review 5.  Novel insights into the organic solute transporter alpha/beta, OSTα/β: From the bench to the bedside.

Authors:  James J Beaudoin; Kim L R Brouwer; Melina M Malinen
Journal:  Pharmacol Ther       Date:  2020-04-02       Impact factor: 12.310

Review 6.  Role of SLC22A1 polymorphic variants in drug disposition, therapeutic responses, and drug-drug interactions.

Authors:  C Arimany-Nardi; H Koepsell; M Pastor-Anglada
Journal:  Pharmacogenomics J       Date:  2015-11-03       Impact factor: 3.550

7.  Genetic variants in transcription factors are associated with the pharmacokinetics and pharmacodynamics of metformin.

Authors:  S Goswami; S W Yee; S Stocker; J D Mosley; M Kubo; R Castro; J A Mefford; C Wen; X Liang; J Witte; C Brett; S Maeda; M D Simpson; M M Hedderson; R L Davis; D M Roden; K M Giacomini; R M Savic
Journal:  Clin Pharmacol Ther       Date:  2014-05-22       Impact factor: 6.875

8.  Sex-differences in renal expression of selected transporters and transcription factors in lean and obese Zucker spontaneously hypertensive fatty rats.

Authors:  Andrea Babelova; Birgitta C Burckhardt; Waja Wegner; Gerhard Burckhardt; Maja Henjakovic
Journal:  J Diabetes Res       Date:  2015-01-29       Impact factor: 4.011

9.  Berry Phenolic Compounds Increase Expression of Hepatocyte Nuclear Factor-1α (HNF-1α) in Caco-2 and Normal Colon Cells Due to High Affinities with Transcription and Dimerization Domains of HNF-1α.

Authors:  Luis M Real Hernandez; Junfeng Fan; Michelle H Johnson; Elvira Gonzalez de Mejia
Journal:  PLoS One       Date:  2015-09-28       Impact factor: 3.240

Review 10.  Development of Human Membrane Transporters: Drug Disposition and Pharmacogenetics.

Authors:  Miriam G Mooij; Anne T Nies; Catherijne A J Knibbe; Elke Schaeffeler; Dick Tibboel; Matthias Schwab; Saskia N de Wildt
Journal:  Clin Pharmacokinet       Date:  2016-05       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.